2篇
您的检索式：作者名="Lily Rodrigues"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | TUMOR NECROSIS FACTOR IS NOT ASSOCIATED WITH INTESTINAL ISCHEMIA/REPERFUSION-INDUCED LUNG INFLAMMATION显示文摘 | Alexandre Learth Soares Fernando Rodrigues Coelho Rodrigo Guabiraba Mamdouh Kamal B. Boris Vargaftig Lily Li Jian Li Wothan Tavares- de-Lima Bernhard Ryffel | 2010 | Shock2010，，3： | 2 |
| 2 | Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan显示文摘AIM:To compare the use of vildagliptin and sulfonylurea with or without metformin in Indian Muslim patients with type 2 diabetes mellitus,fasting during Ramadan.METHODS:This was a 4-wk,multicenter,non-interventional,open-label,observational study.Incidence of hypoglycemic events(HEs),adverse events,and changes in glycosylated hemoglobin A1c(HbA1c),fasting plasma glucose,postprandial plasma glucose and body weight were measured pre-and post-Ramadan.RESULTS:Totally,97 patients were recruited and all completed the study(vildagliptin group,n=55;sulfonylurea group,n=42).HEs were reported in low frequencies in both the vildagliptin and the sulfonylurea groups[0 vs 2(4.8%)patients,respectively].Interestingly,HbA1c reduced by-0.43%(-4.71 mmol/mol)in the vildagliptin group[8.75%(72.10 mmol/mol)to8.32%(67.38 mmol/mol),P=0.009]while in the sulfonylurea group there was a small increase by 0.01%[0.08 mmol/mol;8.64%(70.92 mmol/mol)to 8.65%(71.00 mmol/mol),P=0.958].Higher percentage of vildagliptin-treated patients achieved HbA1c<7.0%(<53 mmol/mol)compared with sulfonylurea(16.4%vs4.8%).Mean decrease in the body weight was 1.2 kg and 0.03 kg,respectively(P<0.001).Both treatment groups were well tolerated during Ramadan.CONCLUSION:Vildagliptin is an attractive treatment option for Indian patients with type 2 diabetes mellitus who are fasting during Ramadan. | Abhijit Shete Aheson Shaikh K Javeed Nayeem Lily Rodrigues Mohamed Sheikamunadeen Sadiq Ali Parag Shah Rajiv Khanna Sarfaraj Majid Sabeer A Rasheed Shehla Shaikh Tawfiqur Rahman | 2013 | World Journal of Diabetes2013，4，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员